Hair Relaxer MDL Reaches 11,877 Cases as Court Sets Bellwether Schedule

The hair relaxer litigation reached 11,877 pending cases as of July 1, 2026, representing the fourth-largest MDL in the country. Judge Mary M. Rowland assumed direct supervision of the trial-selection process, replacing the alternating party-selection system and establishing a court-selected bellwether pool. Case-specific Daubert and summary judgment motions are due November 16, 2026, with initial trials anticipated in 2027.

The litigation, pending in the Northern District of Illinois against L'Oréal, Revlon, Softsheen-Carson, and other cosmetic manufacturers, added approximately 150 cases in June 2026. Filings have expanded steadily since the NIH Sister Study identified that frequent chemical relaxer users were 2.55 times more likely to develop uterine cancer compared to non-users.

Litigation Scale and Scope

The bellwether-eligible pool is narrower than the full docket: the court limited eligibility to cases involving uterine, endometrial, or ovarian cancer with short-form complaints served by February 1, 2024, encompassing roughly 5,230 cases. Judge Rowland expanded the discovery pool from the parties' proposed 16 cases to 40, aiming to produce up to 12 trial-ready files.

Case Timeline

Judicial Management of Bellwethers

Judicial selection of bellwether cases occurs when courts seek to ensure trial files represent the broader docket rather than extreme outliers chosen by either side. The expanded 40-case discovery pool reflects an effort to prepare representative cases for jury evaluation.

A court-appointed Special Master continues to facilitate settlement discussions in parallel with litigation proceedings, with industry analysts projecting formal settlement frameworks could emerge in 2027 following Daubert orders and initial verdicts.

Preparing Case Files for Settlement Tiering

For cases outside the initial trial pool, the current phase provides time to assemble complete medical evidence. Settlement matrices in cancer mass torts typically tier compensation on primary diagnosis, age at onset, treatment intensity (hysterectomy, radiation, chemotherapy), and verified duration of product exposure.

Key medical evidence includes:

1. Oncology and pathology reports confirming diagnosis, staging, and histologic subtype
2. Gynecologic treatment records documenting symptom onset and ruling out competing medical risk factors
3. Surgical records including operative notes for hysterectomy, oophorectomy, or lymph node dissections
4. Product exposure documentation including salon logs, retail purchase histories, and client usage questionnaires

LlamaLab retrieves oncology, gynecology, and surgical records from all treating providers in 4 days on average (with roughly 30-40% returned same-day on electronic requests) and uses insurance data to fill in treatment gaps clients don't always remember. Invoices are itemized per case to flow through as recoverable case disbursements on settlement statements. For additional analysis of qualification criteria, see LlamaLab's hair relaxer litigation update.

Next Steps

Summary

The hair relaxer MDL has reached nearly 12,000 cases with an established bellwether trial schedule. Outcomes from upcoming 2027 trials and the November 2026 Daubert rulings will establish the valuation framework for the litigation.

Law firms holding hair relaxer claims should audit medical and pathology files to ensure cases are fully documented for future settlement tiering.

Sources: Miller & Zois: Hair Relaxer Litigation Updates, Lawsuit Information Center: MDL Case Counts, MDL Update: MDL 3060, Motley Rice: Litigation Timeline, Drugwatch: Hair Relaxer Lawsuits. Case counts current as of July 1, 2026.

This article provides general information about hair relaxer litigation developments and should not be construed as legal or medical advice. Consult with qualified professionals for advice specific to your situation.